Gyre Therapeutics (GYRE) EBT Margin (2010 - 2026)

Gyre Therapeutics (GYRE) has 16 years of EBT Margin data on file, last reported at 41.02% in Q1 2026.

• EBT Margin for Q1 2026 came in at 41.02%, down 6203.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.29% (down 969.0% YoY), and the FY2025 annual result was 4.45%, down 559.0% from the prior year.
• EBT Margin grew to 41.02% in Q1 2026 per GYRE's latest filing, from 52.95% in the prior quarter.
• Over five years, EBT Margin peaked at 45.93% in Q1 2024 and troughed at 1830.73% in Q1 2022.
• A 5-year average of 144.87% and a median of 15.42% in 2024 frame the typical range for EBT Margin.
• On a YoY basis, EBT Margin climbed as much as 185588 bps in 2023 and fell as far as 34691 bps in 2023.
• A 5-year view of EBT Margin shows it stood at 22.46% in 2022, then tumbled by 1544 bps to 369.38% in 2023, then surged by 79 bps to 76.2% in 2024, then jumped by 31 bps to 52.95% in 2025, then advanced by 23 bps to 41.02% in 2026.
• Business Quant data shows GYRE's EBT Margin at 41.02% in Q1 2026, 52.95% in Q4 2025, and 24.96% in Q3 2025.